α-bloker szyty na miarę pacjenta. Leczenie łagodnego rozrostu gruczołu krokowego – bezpieczeństwo, skuteczność i preferencje pacjentów Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
gru 31, 2024
Słowa kluczowe:
antagonista receptora α1-adrenergicznego, łagodny rozrost gruczołu krokowego, objawy z dolnych dróg moczowych
##plugins.themes.bootstrap3.article.main##
Abstrakt
Objawy ze strony dolnych dróg moczowych u mężczyzn często wynikają z łagodnego rozrostu gruczołu krokowego. Leczenie zazwyczaj zaleca się pacjentom z objawami umiarkowanymi lub ciężkimi. Najczęściej stosowane są blokery α1, które rozluźniają mięśnie gładkie w obrębie gruczołu krokowego i szyi pęcherza, poprawiając przepływ moczu. Dobór metody leczenia powinien uwzględniać nasilenie objawów, obecność chorób współistniejących oraz preferencje pacjenta. W procesie decyzyjnym kluczowe jest dokładne omówienie zarówno potencjalnych korzyści terapeutycznych, jak i możliwych działań niepożądanych.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Wiatr, T., Chłosta, P., & Chłosta, M. (2024). α-bloker szyty na miarę pacjenta. Leczenie łagodnego rozrostu gruczołu krokowego – bezpieczeństwo, skuteczność i preferencje pacjentów. Medycyna Faktów , 17(4(65), 487-491. https://doi.org/10.24292/01.MF.0424.09
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. McNeal JG. The prostate gland: morphology and pathobiology. Monogr Urol. 1983; 4: 3-33.
2. Wasserman NF. Benign prostatic hyperplasia: a review and ultrasound classification. Radiol Clin North Am. 2006; 44: 689-710.
3. Girman CJ, Jacobsen SJ, Guess HA et al. Natural history of prostatism: relationship among symptoms, prostate volume and peak urinary flow rate. J Urol. 1995; 153: 1510-5.
4. Lepor H. The pathophysiology of lower urinary tract symptoms in the aging male population. In: Prostatic diseases. Lepor H (ed.). WB Saunders, Philadelphia, PA 2000: 163-96.
5. Jepsen JB, Bruskewitz RC. Clinical manifestations and indications for treatment. In: Prostatic diseases. Lepor H (ed.). WB Saunders, Philadelphia, PA 2000: 127-42.
6. Kaplan SA, McConnell JD, Roehrborn CG et al. for the MTOPS Research Group. Relationship between prostate size and the effect of combination therapy with doxazosin and finasteride versus either drug alone on the clinical progression of benign prostatic hyperplasia. J Urol. 2006; 75: 217-21.
7. Lepor H. a-adrenergic blockers for the treatment of benign prostatic hyperplasia. In: Prostatic diseases. Lepor H (ed.). WB Saunders, Philadelphia, PA 2000: 297-307.
8. Kaplan SA, Gonzalez RR. Phosphodiesterase type 5 inhibitors for the treatment of male lower urinary tract symptoms. Rev Urol. 2007; 9: 73-7.
9. Lepor H, Williford WO, Barry MJ et al. The impact of medical therapy on bother due to symptom, quality of life and global outcome, and factors predicting response. J Urol. 1998; 160: 1358-67.
10. Roehrborn CG, Van Kerrebroeck P, Nordling J. Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. BJU Int. 2003; 92: 257-61.
11. Bartsch G, Muller HR, Oberholzer M et al. Light microscopic stereological analysis of the normal human prostate and of benign prostatic hyperplasia. J Urol. 1979; 122: 487-9.
12. Shapiro E, Becich MJ, Hartanto V et al. The relative proportion of stromal and epithelial hyperplasia as related to the development of clinical BPH. J Urol. 1992; 147: 1293-7.
13. Lepor H. Nonoperative management of benign prostatic hyperplasia. J Urol. 1989; 141: 1283-9.
14. Caine M, Raz S, Zeigler M. Adrenergic and cholinergic receptors in the human prostate, prostatic capsule and bladder neck. Br J Urol. 1975; 27: 193-202.
15. Lepor H, Shapiro E. Characterization of the alpha1 adrenergic receptor in human benign prostatic hyperplasia. J Urol. 1984; 132: 1226-9.
16. Shapiro E, Lepor H. Alpha2 adrenergic receptors in hyperplastic human prostate: identification and characterization using [3H] rauwolscine. J Urol. 1986; 135: 1038-42.
17. Barkin J. Benign prostatic hyperplasia and lower urinary tract symptoms: evidence and approaches for best case management. Can J Urol. 2011; 18(Suppl): 14-9.
18. Schwinn DA, Roehrborn CG. Alpha1-adrenoceptor subtypes and lower urinary tract symptoms. Int J Urol. 2008; 15(3): 193-9.
19. Yamada S, Okura T, Kimura R. In vivo demonstration of alpha(1A)-adrenoceptor subtype selectivity of KMD-3213 in rat tissues. J Pharmacol Exp Ther. 2001; 296(1): 160-7.
20. Tatemichi S, Kobayashi K, Maezawa A et al. Alpha1-adrenoceptor subtype selectivity and organ specificity of silodosin (KMD-3213). Yakugaku Zasshi. 2006; 126(Spec no.): 209-16.
21. Murata S, Taniguchi T, Takahashi M et al. Tissue selectivity of KMD-3213, an alpha(1)-adrenoreceptor antagonist, in human prostate and vasculature. J Urol. 2000; 164(2): 578-83.
22. Kirby R, Andersson KE, Lepor H et al. α1-Adrenoceptor selectivity and the treatment of benign prostatic hyperplasia and lower urinary tract symptoms. Prostate Cancer Prostatic Dis. 2000; 3(2): 76-83.
23. European Medicines Agency. Urorec (silodosin) summary of the European public assessment report (EPAR). 2012.
24. Accord Healthcare Ltd. Terazosin 2 mg tablets. Summary of product characteristics. 2010.
25. Teva Pharmaceuticals. Flectone XL 400 microgram prolonged release tablets (tamsulosin). Summary of product characteristics. 2013.
26. Teva Pharmaceuticals. Petyme 400 micrograms MR Capsules (tamsulosin). Summary of product characteristics. 2013.
27. Ramadhani MZ, Kloping YP, Rahman IA et al. Silodosin as a medical expulsive therapy for distal ureteral stones: A systematic review and meta-analysis. Indian J Urol. 2023; 39(1): 21-6.
28. Bhattar R, Tomar V, Yadav SS et al. Comparison of safety and efficacy of silodosin, solifenacin, tadalafil and their combinations in the treatment of double-J stent-related lower urinary system symptoms: A prospective randomized trial. Turk J Urol. 2018; 44(3): 228-38.
29. Cui Y, Chen J, Zeng F et al. Tamsulosin as a Medical Expulsive Therapy for Ureteral Stones: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Urol. 2019; 201(5): 950-5.
30. Nickel JC, Touma N. α-Blockers for the Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome: An Update on Current Clinical Evidence. Rev Urol. 2012; 14(3-4): 56-64.
31. Mansbart F, Kienberger G, Sonnichsen A et al. Efficacy and safety of adrenergic alpha-1 receptor antagonists in older adults: a systematic review and meta-analysis supporting the development of recommendations to reduce potentially inappropriate prescribing. BMC Geriatr. 2022; 22(1): 771.
32. Chapple C, Andersson KE. Tamsulosin: an overview. World J Urol. 2002; 19(6): 397-404.
33. Velazquez N, Zapata D, Wang HH et al. Medical expulsive therapy for pediatric urolithiasis: Systematic review and meta-analysis. J Pediatr Urol. 2015; 11(6): 321-7.
34. Kang TW, Kim SJ, Chang KD et al. Effect of the symptom-based alpha-blocker treatment on lower urinary tract symptoms in women: systematic review and meta-analysis. Ther Adv Urol. 2021; 13: 17562872211053679.
35. Yoosuf BT, Panda AK, Kt MF et al. Comparative efficacy and safety of alpha-blockers as monotherapy for benign prostatic hyperplasia: a systematic review and network meta-analysis. Sci Rep. 2024; 14(1): 11116.
36. Guo B, Chen X, Wang M et al. Comparative Effectiveness of Tadalafil versus Tamsulosin in Treating Lower Urinary Tract Symptoms Suggestive of Benign Prostate Hyperplasia: A Meta-Analysis of Randomized Controlled Trials. Med Sci Monit. 2020; 26: e923179.
37. Lepor H, Kazzazi A, Djavan B. alpha-blockers for benign prostatic hyperplasia: the new era. Curr Opin Urol. 2012; 22(1): 7-15.
38. Chapple CR, Montorsi F, Tammela TLJ et al. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe. Eur Urol. 2011; 59(3): 342-52.
39. Miyakita H, Yokoyama E, Onodera Y et al. Short-term effects of crossover treatment with silodosin and tamsulosin hydrochloride for lower urinary tract symptoms associated with benign prostatic hyperplasia. Int J Urol. 2010; 17(10): 869-75.
40. Al-Hussaini ZK, McVary KT. Alpha-blockers and intraoperative floppy iris syndrome: ophthalmic adverse events following cataract surgery. Curr Urol Rep. 2010; 11(4): 242-8.
2. Wasserman NF. Benign prostatic hyperplasia: a review and ultrasound classification. Radiol Clin North Am. 2006; 44: 689-710.
3. Girman CJ, Jacobsen SJ, Guess HA et al. Natural history of prostatism: relationship among symptoms, prostate volume and peak urinary flow rate. J Urol. 1995; 153: 1510-5.
4. Lepor H. The pathophysiology of lower urinary tract symptoms in the aging male population. In: Prostatic diseases. Lepor H (ed.). WB Saunders, Philadelphia, PA 2000: 163-96.
5. Jepsen JB, Bruskewitz RC. Clinical manifestations and indications for treatment. In: Prostatic diseases. Lepor H (ed.). WB Saunders, Philadelphia, PA 2000: 127-42.
6. Kaplan SA, McConnell JD, Roehrborn CG et al. for the MTOPS Research Group. Relationship between prostate size and the effect of combination therapy with doxazosin and finasteride versus either drug alone on the clinical progression of benign prostatic hyperplasia. J Urol. 2006; 75: 217-21.
7. Lepor H. a-adrenergic blockers for the treatment of benign prostatic hyperplasia. In: Prostatic diseases. Lepor H (ed.). WB Saunders, Philadelphia, PA 2000: 297-307.
8. Kaplan SA, Gonzalez RR. Phosphodiesterase type 5 inhibitors for the treatment of male lower urinary tract symptoms. Rev Urol. 2007; 9: 73-7.
9. Lepor H, Williford WO, Barry MJ et al. The impact of medical therapy on bother due to symptom, quality of life and global outcome, and factors predicting response. J Urol. 1998; 160: 1358-67.
10. Roehrborn CG, Van Kerrebroeck P, Nordling J. Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. BJU Int. 2003; 92: 257-61.
11. Bartsch G, Muller HR, Oberholzer M et al. Light microscopic stereological analysis of the normal human prostate and of benign prostatic hyperplasia. J Urol. 1979; 122: 487-9.
12. Shapiro E, Becich MJ, Hartanto V et al. The relative proportion of stromal and epithelial hyperplasia as related to the development of clinical BPH. J Urol. 1992; 147: 1293-7.
13. Lepor H. Nonoperative management of benign prostatic hyperplasia. J Urol. 1989; 141: 1283-9.
14. Caine M, Raz S, Zeigler M. Adrenergic and cholinergic receptors in the human prostate, prostatic capsule and bladder neck. Br J Urol. 1975; 27: 193-202.
15. Lepor H, Shapiro E. Characterization of the alpha1 adrenergic receptor in human benign prostatic hyperplasia. J Urol. 1984; 132: 1226-9.
16. Shapiro E, Lepor H. Alpha2 adrenergic receptors in hyperplastic human prostate: identification and characterization using [3H] rauwolscine. J Urol. 1986; 135: 1038-42.
17. Barkin J. Benign prostatic hyperplasia and lower urinary tract symptoms: evidence and approaches for best case management. Can J Urol. 2011; 18(Suppl): 14-9.
18. Schwinn DA, Roehrborn CG. Alpha1-adrenoceptor subtypes and lower urinary tract symptoms. Int J Urol. 2008; 15(3): 193-9.
19. Yamada S, Okura T, Kimura R. In vivo demonstration of alpha(1A)-adrenoceptor subtype selectivity of KMD-3213 in rat tissues. J Pharmacol Exp Ther. 2001; 296(1): 160-7.
20. Tatemichi S, Kobayashi K, Maezawa A et al. Alpha1-adrenoceptor subtype selectivity and organ specificity of silodosin (KMD-3213). Yakugaku Zasshi. 2006; 126(Spec no.): 209-16.
21. Murata S, Taniguchi T, Takahashi M et al. Tissue selectivity of KMD-3213, an alpha(1)-adrenoreceptor antagonist, in human prostate and vasculature. J Urol. 2000; 164(2): 578-83.
22. Kirby R, Andersson KE, Lepor H et al. α1-Adrenoceptor selectivity and the treatment of benign prostatic hyperplasia and lower urinary tract symptoms. Prostate Cancer Prostatic Dis. 2000; 3(2): 76-83.
23. European Medicines Agency. Urorec (silodosin) summary of the European public assessment report (EPAR). 2012.
24. Accord Healthcare Ltd. Terazosin 2 mg tablets. Summary of product characteristics. 2010.
25. Teva Pharmaceuticals. Flectone XL 400 microgram prolonged release tablets (tamsulosin). Summary of product characteristics. 2013.
26. Teva Pharmaceuticals. Petyme 400 micrograms MR Capsules (tamsulosin). Summary of product characteristics. 2013.
27. Ramadhani MZ, Kloping YP, Rahman IA et al. Silodosin as a medical expulsive therapy for distal ureteral stones: A systematic review and meta-analysis. Indian J Urol. 2023; 39(1): 21-6.
28. Bhattar R, Tomar V, Yadav SS et al. Comparison of safety and efficacy of silodosin, solifenacin, tadalafil and their combinations in the treatment of double-J stent-related lower urinary system symptoms: A prospective randomized trial. Turk J Urol. 2018; 44(3): 228-38.
29. Cui Y, Chen J, Zeng F et al. Tamsulosin as a Medical Expulsive Therapy for Ureteral Stones: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Urol. 2019; 201(5): 950-5.
30. Nickel JC, Touma N. α-Blockers for the Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome: An Update on Current Clinical Evidence. Rev Urol. 2012; 14(3-4): 56-64.
31. Mansbart F, Kienberger G, Sonnichsen A et al. Efficacy and safety of adrenergic alpha-1 receptor antagonists in older adults: a systematic review and meta-analysis supporting the development of recommendations to reduce potentially inappropriate prescribing. BMC Geriatr. 2022; 22(1): 771.
32. Chapple C, Andersson KE. Tamsulosin: an overview. World J Urol. 2002; 19(6): 397-404.
33. Velazquez N, Zapata D, Wang HH et al. Medical expulsive therapy for pediatric urolithiasis: Systematic review and meta-analysis. J Pediatr Urol. 2015; 11(6): 321-7.
34. Kang TW, Kim SJ, Chang KD et al. Effect of the symptom-based alpha-blocker treatment on lower urinary tract symptoms in women: systematic review and meta-analysis. Ther Adv Urol. 2021; 13: 17562872211053679.
35. Yoosuf BT, Panda AK, Kt MF et al. Comparative efficacy and safety of alpha-blockers as monotherapy for benign prostatic hyperplasia: a systematic review and network meta-analysis. Sci Rep. 2024; 14(1): 11116.
36. Guo B, Chen X, Wang M et al. Comparative Effectiveness of Tadalafil versus Tamsulosin in Treating Lower Urinary Tract Symptoms Suggestive of Benign Prostate Hyperplasia: A Meta-Analysis of Randomized Controlled Trials. Med Sci Monit. 2020; 26: e923179.
37. Lepor H, Kazzazi A, Djavan B. alpha-blockers for benign prostatic hyperplasia: the new era. Curr Opin Urol. 2012; 22(1): 7-15.
38. Chapple CR, Montorsi F, Tammela TLJ et al. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe. Eur Urol. 2011; 59(3): 342-52.
39. Miyakita H, Yokoyama E, Onodera Y et al. Short-term effects of crossover treatment with silodosin and tamsulosin hydrochloride for lower urinary tract symptoms associated with benign prostatic hyperplasia. Int J Urol. 2010; 17(10): 869-75.
40. Al-Hussaini ZK, McVary KT. Alpha-blockers and intraoperative floppy iris syndrome: ophthalmic adverse events following cataract surgery. Curr Urol Rep. 2010; 11(4): 242-8.